JANX · Categories · Form 4

JANX - SEC Form 4 insider transactions

Janux Therapeutics Inc. (JANX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for JANX

• 21d
  Vice President, Accounting Dobek Maria sold $28,878 worth of shares (2,038 units at $14.17), decreasing direct ownership by 6% to 32,270 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 119d
  Chief Medical Officer Go William was granted 44,000 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 151d
  President and CEO Campbell David Alan sold $110,829 worth of shares (8,072 units at $13.73) and was granted 96,600 shares, increasing direct ownership by 30% to 381,582 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 151d
  Chief Scientific Officer Diraimondo Thomas sold $34,394 worth of shares (2,505 units at $13.73) and was granted 31,400 shares, increasing direct ownership by 23% to 155,825 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 151d
  Chief Medical Officer Mciver Zachariah sold $37,263 worth of shares (2,714 units at $13.73) and was granted 29,000 shares, increasing direct ownership by 101% to 52,286 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 151d
  Chief Technical Officer Winter Charles M. sold $32,966 worth of shares (2,401 units at $13.73) and was granted 28,600 shares, increasing direct ownership by 33% to 106,321 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 151d
  Chief Business Officer Meyer Andrew Hollman sold $25,799 worth of shares (1,879 units at $13.73), decreasing direct ownership by 2% to 83,095 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 151d
  Vice President, Accounting Dobek Maria sold $20,073 worth of shares (1,462 units at $13.73) and was granted 18,935 shares, increasing direct ownership by 104% to 34,308 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 151d
  Chief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel was granted 36,000 shares, increasing direct ownership by 82% to 80,000 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 182d
  Chief Business Officer Meyer Andrew Hollman exercised 3,333 shares at a strike of $10.59 and sold $109,929 worth of shares (3,333 units at $32.98) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 201d
  Chief Business Officer Meyer Andrew Hollman exercised 3,333 shares at a strike of $10.59 and sold $99,990 worth of shares (3,333 units at $30.00) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 216d
  Chief Business Officer Meyer Andrew Hollman exercised 16,665 shares at a strike of $6.76 and sold $500,987 worth of shares (16,665 units at $30.06) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 355d
  Director Ra Capital Management, L.P. was granted 3,750 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 355d
  Director Dobmeier Eric was granted 3,750 shares, increasing direct ownership by 60% to 9,981 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 355d
  Director Gujrathi Sheila was granted 3,750 shares, increasing direct ownership by 3% to 118,889 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 355d
  Director Barrett Ronald W was granted 3,750 shares, increasing direct ownership by 150% to 6,250 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 355d
  Director Mcnulty Alana B. was granted 3,750 shares, increasing direct ownership by 150% to 6,250 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 355d
  Director Capps Vickie L was granted 3,750 shares, increasing direct ownership by 5% to 74,098 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 355d
  Director Hernday Natasha was granted 3,750 shares, increasing direct ownership by 75% to 8,731 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 355d
  Director Simson Jake was granted 3,750 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 355d
  Director Kung Winston was granted 3,750 shares, increasing direct ownership by 150% to 6,250 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 364d
  Chief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel was granted 44,000 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 397d
  Chief Business Officer Meyer Andrew Hollman exercised 3,333 shares at a strike of $4.21 and sold $106,745 worth of shares (3,333 units at $32.03) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 406d
  Chief Business Officer Meyer Andrew Hollman exercised 3,334 shares at a strike of $4.21 and sold $100,020 worth of shares (3,334 units at $30.00) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 455d
  Chief Business Officer Meyer Andrew Hollman exercised 3,334 shares at a strike of $4.21 and sold $107,174 worth of shares (3,334 units at $32.15) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 483d
  Chief Business Officer Meyer Andrew Hollman sold $140,999 worth of shares (3,334 units at $42.29) and exercised 3,334 shares at a strike of $4.21 (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 511d
  President and CEO Campbell David Alan sold $300,004 worth of shares (5,000 units at $60.00), decreasing direct ownership by 2% to 293,054 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 516d
  President and CEO Campbell David Alan was granted 81,000 shares, increasing direct ownership by 37% to 298,054 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 516d
  Chief Medical Officer Mciver Zachariah was granted 26,000 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 516d
  Chief Scientific Officer Diraimondo Thomas was granted 24,000 shares, increasing direct ownership by 23% to 129,719 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 516d
  Vice President, Accounting Dobek Maria was granted 14,000 shares, increasing direct ownership by 1,400,000% to 14,001 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 516d
  Chief Strategy Officer Robinson Byron was granted 28,000 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 516d
  Chief Technical Officer Winter Charles M. was granted 23,000 shares, increasing direct ownership by 42% to 77,288 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 516d
  Chief Business Officer Meyer Andrew Hollman was granted 18,000 shares and sold $731,785 worth of shares (13,334 units at $54.88), increasing direct ownership by 6% to 82,139 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 523d
  President and CEO Campbell David Alan sold $1,404,805 worth of shares (25,000 units at $56.19), decreasing direct ownership by 10% to 217,054 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 530d
  Chief Business Officer Meyer Andrew Hollman exercised 9,881 shares at a strike of $20.24, increasing direct ownership by 15% to 77,473 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 547d
  President and CEO Campbell David Alan sold $1,005,000 worth of shares (15,000 units at $67.00), decreasing direct ownership by 6% to 242,054 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 553d
  President and CEO Campbell David Alan sold $1,289,879 worth of shares (25,000 units at $51.60), decreasing direct ownership by 9% to 257,054 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 573d
  Director Gujrathi Sheila acquired 4,611 shares, increasing direct ownership by 4% to 115,139 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 573d
  Director Capps Vickie L acquired 2,305 shares, increasing direct ownership by 3% to 70,348 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 581d
  President and CEO Campbell David Alan sold $1,338,559 worth of shares (25,000 units at $53.54), decreasing direct ownership by 8% to 282,054 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 587d
  Large owner Lichter Jay exercised 3,815 shares at a strike of $17.29 and sold $178,084 worth of shares (3,815 units at $46.68) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 593d
  Large owner Avalon Ventures Xi, L.P. sold $77,472,371 worth of shares (1,673,128 units at $46.30) and exercised 12,284 shares at a strike of $18.07 (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 611d
  Large owner Avalon Ventures Xi, L.P. sold $14,452,394 worth of shares (307,779 units at $46.96) and exercised 2,671 shares at a strike of $18.07 (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 614d
  Chief Business Officer Meyer Andrew Hollman exercised 50,000 shares at a strike of $4.21 and sold $2,297,755 worth of shares (50,000 units at $45.96) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 614d
  Chief Scientific Officer Diraimondo Thomas sold $231,716 worth of shares (5,000 units at $46.34), decreasing direct ownership by 5% to 97,938 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 614d
  President and CEO Campbell David Alan sold $1,157,641 worth of shares (25,000 units at $46.31), decreasing direct ownership by 8% to 307,054 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 629d
  Large owner Avalon Ventures Xi, L.P. sold $21,153,619 worth of shares (451,091 units at $46.89) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 631d
  Large owner Avalon Ventures Xi, L.P. exercised 2,099 shares at a strike of $18.03 and sold $10,172,364 worth of shares (242,182 units at $42.00) (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 679d
  Amendment: Director Dobmeier Eric was granted 1,231 shares, increasing direct ownership by 25% to 6,231 units (SEC Form 4)

  4/A - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 679d
  Amendment: Director Hernday Natasha was granted 1,231 shares, increasing direct ownership by 25% to 6,231 units (SEC Form 4)

  4/A - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 681d
  Director Dobmeier Eric was granted 7,500 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 681d
  Director Hernday Natasha was granted 7,500 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 705d
  Director Ra Capital Management, L.P. was granted 2,500 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 705d
  Director Gujrathi Sheila was granted 2,500 shares, increasing direct ownership by 2% to 110,528 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 705d
  Director Kung Winston was granted 2,500 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 705d
  Director Mcnulty Alana B. was granted 2,500 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 705d
  Director Lichter Jay was granted 2,500 shares, increasing direct ownership by 55% to 7,083 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 705d
  Director Barrett Ronald W was granted 2,500 shares (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
• 705d
  Director Capps Vickie L was granted 2,500 shares, increasing direct ownership by 4% to 68,043 units (SEC Form 4)

  4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

Other JANX categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends